目的：比较依托考昔与美洛昔康治疗急性痛风的临床效果及其用药安全性。方法选择2010年1月~2013年1月本院收治的急性痛风患者120例为研究对象，随机分为依托考昔组及美洛昔康组，每组60例。依托考昔组服用依托考昔120 mg/d，美洛昔康组服用美洛昔康15 mg/d，测定患者疼痛的自我评分并记录药物不良反应。结果治疗后，两组患者的疼痛评分均下降，且依托考昔组的疼痛改善情况明显优于美洛昔康组(P<0.05)。依托考昔组不良反应发生率为30.0%，美洛昔康组不良反应发生率为33.3%，两组差异无统计学意义(P跃0.05)。结论依托考昔治疗急性痛风的临床效果优于美洛昔康。%Objective To analyze the clinical effect and safety of etoricoxib and meloxicam in treating acute gout. Methods 120 cases of patients with acute gout treated in our hospital from January 2010 to January 2013 were selected as research objects and were divided into etoricoxib group and meloxicam group randomly,each group for 60 cases. Etoricoxib group were treated with etoricoxib,120 mg/d.Meloxicam group were treated with meloxicam,15 mg/d.The self score of pain of patients was measured,and the adverse reactions were recorded. Results After treatment,the joint pain scores of two groups were down,and etoricoxib group improved more better than that of meloxicam group,the differences were sinificant (P<0.05).The incidence of etoricoxib group was 30.0%,and the meloxicam group was 33.3%, there was no significant difference between the two groups (P>0.05). Conclusion The clinical efficacy of etoricoxib is better than that of meloxicam.
展开▼
